• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • Pay 2021 Membership Dues
  • Our Membership
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Find a Pediatric Dermatologist (from SPD)
        • Clinical Trials
        • Patient Advisory Committee
        • Learn more about PeDRA’s efforts to build capacity for patient engagement in pediatric dermatology research.

           

  • Education and Events
        • Virtual Education
        • PeDRA Podcasts
        • Mentorship Program
        • Early Career Support
        • 2021 PeDRA Annual Conference
        • Past PeDRA Conferences
        • Upcoming Events
        • Education and Events Archive
        • Save the Date!

          The 2021 PeDRA Annual Conference will take place October 14-16, 2021 in Bethesda, MD.

           

  • Research
        • Grants & Awards
        • Studies
        • Focused Study Groups
        • Publications
        • Clinical Trials
        • Spring Funding Opportunities

          2021 Research Fellowships
          due April 1
          2021 Childhood Eczema Challenge Grant
          due May 4

  • About
        • Mission & Vision
        • Leadership & Staff
        • Annual Reports
        • News Archive
        • Our Supporters
        • Our Membership
        • Our Committees
        • Getting to Know You
        • PeDRA is an independent 501(c)(3) nonprofit organization driven by the mission to create, inspire, and sustain research to prevent, treat, and cure childhood skin disease.

  • Member Login

A Pilot Study to Assess the Impact of a Validated Illustrated Eczema Action Plan on Pediatric Patients

November 10, 2019 By Mike Siegel

Principal Investigator:

Alana McEvoy, MD
University of Ottawa

Overview:

Our group has developed and validated an illustrated eczema action plan (EAP) that uses the advantages of infographics, simple language, and multidimensional function as an educational tool, prescription, and method of communication with other healthcare professionals to improve the ability of patients and parents to manage eczema. The objective of this study is to assess the impact of the EAP on eczema severity, quality of life, and retention of key counselling points.

In this is a prospective study, in which new eczema patients are randomly assigned to receive either 1) standard verbal counselling 2) an illustrated EAP along with standard verbal counselling. Objective eczema severity at 3 months is the primary outcome (EASI). Secondary outcomes include: severity of eczema as rated by the parents/caregiver or patient (POEM and PO-SCORAD); and the patient’s quality of life with atopic dermatitis (DLQI, CLDQI, or IDQOL) as well as comprehension and recall of key information about eczema. These outcomes are evaluated at baseline, one-month, and 3 months after the initial visit.

We anticipate that the EAP will have a positive impact of the severity of the child’s eczema and the child’s QoL. We also anticipate an improvement in comprehension and recall of eczema-related information.

Status:

This study was funded as a 2018 PeDRA Pilot Grant and a manuscript is currently under review for publication.

Filed Under: Inflammatory Skin Disease

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
Sign up to receive emails from PeDRA
Join PeDRA
Donate

Copyright © 2021 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy